News | September 02, 2021
Morpen Laboratories to transfer its medical devices business to a wholly owned subsidiary
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
In H1FY21, it attracted PE deals worth US $ 1.6 billion compared to US $ 3 billion in CY2020
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
Domestic market and developing countries will need doses of Indian vaccines
The company has strong product launches both in India and overseas
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Filing for WHO Emergency Use Authorisation this month
This robust growth has come despite the raging pandemic for most part of the quarter
Subscribe To Our Newsletter & Stay Updated
